Alnylam Pharmaceuticals (ALNY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Alnylam Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$249.99+1.31(0.01%)Pre-market

Market Cap

$32.80B

P/E

40.6x

P/S

6.8x

P/B

24.2x

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

How this company scores

ExcellentMetricSide Score: 83/100

Strongest: Growth (23/25); weakest: Cash & Earnings Quality (19/25).

Profitability22/25

Growth23/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality19/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 40.6x5y range 40.6x – 1350.2x

Currently below its 4-quarter median.

P/S · 6.8x5y range 6.8x – 43.4x

Currently below its 20-quarter median.

P/B · 24.2x5y range 24.2x – 1093.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $32.80B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.80B
Q. Revenue: $1.29B
TTM EBITDA: $999.78M
TTM Op. Income: $999.78M
Q. Op. Income: $231.44M
TTM Net Income: $807.99M
Q. Net Income: $164.49M
EPS: $1.23
Shares Out.: $133.61M

$4.80B in TTM revenue grew 95.1% YoY, reaching $1.29B last quarter. TTM EBITDA of $999.78M and TTM operating income of $999.78M show growth is flowing through to the bottom line. TTM net income of $807.99M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 76.9%
EBITDA Margin: 17.9%
Op. Margin: 17.9%
Net Margin: 12.7%

Op. margin of 17.9% is up 20.0% YoY — cost efficiency is improving. Net margin at 12.7% and gross margin of 76.9% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 956% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 40.6x
P/S Ratio: 6.8x
P/B Ratio: 24.2x

At 40.6x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 6.8x and P/B of 24.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $5.56B
Cash: $1.71B
Long-Term Debt: $1.01B
Book Value: $1.35B
D/E Ratio: 0.7
Debt/EBITDA: 4.4

With $5.56B in assets and $1.01B in long-term debt, D/E is 0.7and book value is $1.35B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $326.72M
TTM Free Cash Flow: $793.95M
FCF Margin: 16.5%
FCF / Net Income: 1.0

TTM FCF of $793.95M on $326.72M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.